A liquid chromatography mass spectrometry assay for determination of PD168393, a specific and irreversible inhibitor of erbB membrane tyrosine kinases, in rat serum

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 876, Issue 2, 2008, Pages 219-224

  Prasain, Jeevan K ^a   Arabshahi, Alireza ^a   Moore, Ray ^c   Barnes, Stephen ^a,c   Carroll, Steven L ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

LC MS MS; PD168393; Quantification; Serum

Indexed keywords

ACIDS; AMINO ACIDS; ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; CHROMATOGRAPHIC ANALYSIS; CONCENTRATION (PROCESS); CUSTOMER SATISFACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; IONIZATION OF LIQUIDS; ISOMERS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY; METHANOL; ORGANIC ACIDS; QUALITY ASSURANCE; QUALITY FUNCTION DEPLOYMENT; SPECTROMETERS; SPECTROMETRY; SPECTRUM ANALYSIS; TOTAL QUALITY MANAGEMENT;

ATMOSPHERIC PRESSURE CHEMICAL IONIZATIONS; CHROMATOGRAPHIC SEPARATIONS; CONCENTRATION RANGES; FUTURE METHODS; INTERNAL STANDARDS; JUPITER; LC-MS/MS; LIQUID CHROMATOGRAPHY MASS SPECTROMETRIES; LOWER LIMIT OF QUANTIFICATIONS; PD168393; PHARMACOKINETIC STUDIES; POSITIVE ION MODES; PROTEIN PRECIPITATIONS; QUANTIFICATION; RAT SERUMS; REACTION MONITORING; SERUM; SERUM SAMPLES; SIMPLE LIQUIDS; TRIAZOLAM; TYROSINE KINASES; VALIDATED METHODS;

BODY FLUIDS;

N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; TRIAZOLAM;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANIMALS; CHROMATOGRAPHY, LIQUID; QUINAZOLINES; RATS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 56549092311     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.10.046     Document Type: Article

References (14)

1. Kim H., and Muller W.J. Exp. Cell Res. 253 (1999) 78
2. Fry D.W. Pharmacol. Ther. 82 (1999) 207
3. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., and Dobrusin E.M. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 12022
4. Stonecypher M.S., Byer S.J., Grizzle W.E., and Carroll S.L. Oncogene 24 (2005) 5589
5. Darmoul D., Gratio V., Devaud H., Peiretti F., and Laburthe M. Mol. Cancer Res. 2 (2004) 514
6. Pu Y.S., Hsieh M.W., Wang C.W., Liu G.Y., Huang C.Y., Lin C.C., Guan J.Y., Lin S.R., and Hour T.C. Biochem. Pharmacol. 71 (2006) 751
7. Bose R., Molina H., Patterson A.S., Bitok J.K., Periaswamy B., Bader J.S., Pandey A., and Cole P.A. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 9773
8. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Clin. Cancer Res. 6 (2000) 4885
9. U.S. Food and Drug Administration: Centre for Drug Evaluation and Research: Guidance for Industry. Bioanalytical Method Validation (2001) www.fda.gov/cder/quidance/4252fnl.htm.
10. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yacobi A. Pharm. Res. 17 (2000) 1551
11. Rosing H., Man W., Doyle E., Bult A., and Beijnen J.H. J. Liq. Chromatogr. Relat. Technol. 23 (2000) 329
12. Schuhmacher J., Zimmer D., Tesche F., and Pickard V. Rapid Commun. Mass Spectrom. 17 (2003) 1950
13. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 70 (1998) 882
14. Chavez-Eng C.M., Constanzer M.L., and Matuszewski B.K. J. Pharm. Biomed. Anal. 35 (2004) 1213